Clinical Study
Validation of the Combined Model Based on Platelet Count and Albumin to Rule out High-Risk Varices in Liver Cirrhosis
Table 1
Main characteristics of the study.
| | Variables | Total cohort, | Beijing cohort, | Xingtai cohort, |
| | Male (%) | 187 (64.0) | 57 (54.8) | 130 (69.1) | | Age (years) | 52 (43-60.5) | 52 (43-60) | 52.5 (43-61.5) | | BMI | 23.2 (21.4-25.2) | 23.2 (21.4-25.2) | NA | | Etiology | | | | | Hepatitis B | 174 (59.6) | 36 (34.6) | 138 (73.4) | | Hepatitis C | 4 (1.4) | 0 (0) | 4 (2.1) | | PBC | 8 (2.7) | 5 (4.8) | 3 (1.6) | | Alcohol | 12 (4.1) | 11 (10.6) | 1 (0.5) | | Others | 93 (31.8) | 52 (50.0) | 41 (21.8) | | Child-Pugh | | | | | A | 245 (83.9) | 84 (80.8) | 161 (85.6) | | B | 47 (16.1) | 20 (19.2) | 27 (14.4) | | Platelets (103/μL) | 111 (80-162.5) | 97 (68-139.5) | 118.5 (88.5-171) | | ALT (IU/L) | 26.9 (19-41.9) | 22 (16-29.5) | 31.5 (21.3-50) | | ALB (g/L) | 41 (36.3-44.1) | 37.5 (34.5-41.1) | 42.2 (38.5-45.7) | | Bilirubin (μM/L) | 20.1 (14-30.1) | 21 (15.1-30.6) | 19 (14-28.8) | | INR | 1.2 (1.1-1.3) | 1.2 (1.1-1.4) | 1.2 (1.1-1.3) | | TE† LSM (kPa) | 19.8 (12-34.8) | 19.8 (12-34.8) | NA | | High-risk varices (%) | 47 (16.1) | 19 (18.3) | 28 (14.9) | | Any varices | 142 (48.6) | 54 (51.9) | 88 (46.8) | | With RESIST-HCV criteria | 109 | 26 | 83 | | With RESIST-HCV criteria who had HRV | 1 | 1 | 0 |
|
|
Continuous variables are expressed as median (interquartile range) unless indicated. †TE was available in 90 patients. Abbreviations: ALB: albumin; ALT: alanine aminotransferase; HRV: high-risk varices; INR: international normalized ratio; LSM: liver stiffness measurement; PBC: primary biliary cholangitis; TE: transient elastography.
|
